Document 0674
 DOCN  M9440674
 TI    Pentoxifylline and meclofenamic acid treatment reduces clinical
       manifestations in a murine model of AIDS.
 DT    9404
 AU    Stadler I; Chadha KC; Nakeeb S; Toumbis C; Butsch J; Mathur N;
       Munschauer F; Vladutiu A; Satchidanand SK; Ambrus JL; Department of
       Internal Medicine, Buffalo General Hospital, State; University of New
       York.
 SO    J Pharmacol Exp Ther. 1994 Jan;268(1):10-3. Unique Identifier : AIDSLINE
       MED/94133106
 AB    C57/BL/6 mice infected with LP-BM5 MuLV virus developed an AIDS-like
       disease (MAIDS) with splenomegaly, leukopenia, thrombocytopenia, anemia,
       decreased numbers of helper/inducer and suppressor/cytotoxic T-cells and
       decreased production of interferon alpha. We have shown previously that
       HIV-associated Kaposi's sarcoma tissue contains high levels of
       prostaglandin E2 (PgE2), and this inhibits interferon synthesis through
       a cAMP-dependent second-messenger process. In this study we treated
       groups of MAIDS-infected mice with combinations of pentoxifylline, an
       agent which increases cAMP and inhibits phosphodiesterases, and sodium
       meclofenamic acid, a PgE2 inhibitor. Treated mice showed: 1)
       significantly higher total leukocyte and platelet counts, 2) higher
       total L3T4+ (helper/inducer) and Lyt-2+ (suppressor-cytotoxic) T-cell
       population. Pathologic examination also showed significantly less
       hepatosplenomegaly and lymphadenopathy in animals treated with
       pentoxifylline and meclofenamic acid. Partly, PgE2-induced suppression
       of interferon alpha production may mediate expression of retrovirus
       infection in this murine model of AIDS.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY  Animal  Cells, Cultured
       Disease Models, Animal  Male  Meclofenamic Acid/*THERAPEUTIC USE  Mice
       Mice, Inbred C57BL  Murine Acquired Immunodeficiency Syndrome/*DRUG
       THERAPY  Pentoxifylline/*THERAPEUTIC USE  Support, Non-U.S. Gov't
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).